Growth hormone replacement therapy in adults with growth hormone deficiency: Benefits and cost-effectiveness

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 6, Issue 2, 2006, Pages 131-138

  Tanriverdi, Fatih ^a   Unluhizarci, Kursad ^a   Kelestimur, Fahrettin ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Cardiovascular risk factors; Cost effectiveness; Growth hormone; Growth hormone deficiency; Growth hormone replacement therapy; Lipid profile; Osteoporosis; Quality of life; Recombinant human growth hormone

Indexed keywords

CORTICOSTEROID; GLUCAGON; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; HUMAN GROWTH HORMONE; INSULIN; PLACEBO; SEX HORMONE; THYROXINE;

ARTHRALGIA; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG DOSE REGIMEN; DRUG MONITORING; DRUG SAFETY; EDEMA; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INSULIN TOLERANCE TEST; LIPID ANALYSIS; MYALGIA; ONSET AGE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 33646075960     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.6.2.131     Document Type: Review

References (82)

1. Cuneo, RC, Salomon F, McGauley GA et al. The growth hormone deficiency syndrome in adults. Clin. Endocrinol. (Oxf.) 37(5), 387-397 (1992).
2. Bengtsson BA, Eden S, Loon L et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol, Metab. 76(2), 309-317 (1993).
3. Cuneo RC, Judd S, Wallace JD et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin. Endocrinol. Metab. 83(1), 107-116 (1998).
4. Cuneo RC, Salomon F, Watts GF et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 42(12), 1519-1523 (1993).
5. Rosen T, Eden S, Larson G et al. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh.) 129(3), 195-200 (1993).
6. Burman P, Broman JE, Hetta J et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J. Clin. Endocrinol. Metab. 80(12), 3585-3590 (1995).
7. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K et al. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J. Endocrinol. 137(3), 240-245 (1997).
8. Beshyah SA, Henderson A, Niththyananthan R et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J. Clin. Endocrinol. Metab. 80(2), 356-363 (1995).
9. Russell-Jones DL, Weissberger AJ, Watts GF. The effects of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficiency. Endocrinolol, Metab. 1(Suppl.)(1994) (Abstract 13).
10. McKenna SP, Koppeschaar H et. al. The impact of replacement GH on the quality of life of patients: result of a clinical trial in The Netherlands. Endrinol. Metab. 4 (Suppl. B), 167 (1997).
11. Baum HB, Biller BM, Finkelstein JS et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann. Intern. Med. 125(11), 883-890 (1996).
12. O'Halloran DJ, Tsatsoulis A, Whitehouse RW et al. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J. Clin. Endocrinol. Metab. 76(5), 1344-1348 (1993).
13. Cook DM. Shouldn't adults with growth hormone deficiency be offered growth hormone replacement therapy? Ann. Intern. Med. 137(3), 197-201 (2002).
14. Isley WL. Growth hormone therapy for adults: not ready for prime time? Ann. Intern. Med. 1370), 190-196 (2002).
15. Arwert LI, Roos JC, Lips P et al. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin. Endocrinol (Oxf.) 63(3), 310-316 (2005).
16. Arwert LI, Deijen JB, Muller M et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm. Behav. 47(3), 343-349 (2005).
17. Gibney J, Wallace JD, Spinks T et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J. Clin. Endocrinol. Metab. 84(8), 2596-2602 (1999).
18. Monson JP. Long-term experience with GH replacement therapy: efficacy and safety. Eur. J. Endocrinol. 148 (Suppl 2), 9-14 (2003).
19. Wilhelm B, Kann PH. Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults. Med. Klin. (Munich) 99(10), 569-577 (2004).
20. Abs R, Feldt-Rasmussen U. Gmuth Hormone Deficiency in Adult. 10 Years of KIMS. Oxford PharmaGenesis, Oxford, UK (2004).
21. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336(8710), 285-288 (1990).
22. Sonksen PH. Replacement therapy in hypothalamo-pituitary insufficiency after childhood: management in the adult. Horm. Res. 33(Suppl. 4), 45-51 (1990).
23. Kelestimur F, Jonsson P, Molvalilar S et al. Sheeha's syndrome: baseline characteristics and effect of 2 years of growth hormone replacement therapy in 91 patients in KIMS. Eur. J. Endocrinol 152(4), 581-587 (2005).
24. Tanriverdi F, Unluhizarci K, Kula M et al. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome. Growth Horm. IGF Res. 15(3), 231-237 (2005).
25. Benvenga S, Campenni A, Ruggeri RM et al. Clinical review 113: hypopituitarism secondary to head trauma. J. Clin. Endocrinol Metab. 85(4), 1353-1361 (2000).
26. Kelly DF, Gonzalo IT, Cohan P et al. Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J. Neurosurg. 93(5), 743-752 (2000).
27. Springer J, Chollet A. A traumatic car crash. Lancet 357, 1848 (2001).
28. Kelestimur F, Tanriverdi F, Atmaca H et al. Boxing as a sport activity associated with isolated GH deficiency. J. Endocrinol. Invest. 27(11), RC28-RC32 (2004).
29. Cuneo RC, Salomon F, Wiles CM et al. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mriss and strength. J. Appl. Physiol. 70(2), 688-694 (1991).
30. Attanasio AF, Lamberts SW, Matranga AM et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J. Clin. Endocrinol. Metab. 82(l), 82-88 (1997).
31. Johannsson G, Bjarnason R, Bramnert M et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J. Clin. Endocrinol. Metab. 81(4), 1575-1581 (1996).
32. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J. Clin. Endocrinol. Metab. 83(2), 379-381 (1998).
33. Hoeck HC, Vestergaard P, Jakobsen PE et al. Test of growth hormone secretion in adults: poor reproducibility of the insulin tolerance test. Eur. J. Endocrinol. 133(3), 305-312 (1995).
34. Popovic V, Leal A, Micic D et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 356(9236), 1137-1142 (2000).
35. Popovic V, Pekic S, Micic D et al. Evaluation of the reproducibility of the GHRH plus GHRP-6 test of growth hormone reserve in adults. Clin. Endocrinol. (Oxf.) 60(2), 185-191 (2004).
36. Juul A, Kastrup KW, Pedersen SA et al. Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. J. Clin. Endocrinol. Metab. 82(4), 1195-1201 (1997).
37. Jorgensen JO, Pedersen SA, Laurberg P et al. Effects of growth hormone therapy on thyroid function of growth hormone-deficient adults with and without concomitant thyroxine-substituted central hypothyroidism. J. Clin. Endocrinol. Metab. 69(6), 1127-1132 (1989).
38. Salomon F, Cuneo RC, Hesp R et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N. Engl. J. Med. 321(26), 1797-1803 (1989).
39. Janssen YJ, Frolich M, Roelfsema F. A low starting dose of genotropin in growth hormone-deficient adults. J. Clin. Endocrinol. Metab. 82(1), 129-135 (1997).
40. Bollerslev J, Hallen J, Fougner KJ et al. Low-dose GH improves exercise capacity in adults with GH deficiency: effects of a 22-month placebo-controlled, crossover trial. Eur. J. Endocrinol. 153(3), 379-387 (2005).
41. Hoffman AR, Strasburger CJ, Zagar A et al. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. J. Clin. Endocrinol. Metab. 89(7), 3224-3233 (2004).
42. Cook DM, Biller BM, Vance ML et al. The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults. J. Clin. Endocrinol. Metab. 87(10), 4508-4514 (2002).
43. Tomlinson JW, Holden N, Hills RK et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357(9254), 425-431 (2001).
44. Gibney J, Wallace JD, Spinks TJ et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin. Endocrinol. Metab. 84, 2596-2602 (1999).
45. Maison P. Griffin S, Beglah-Nicoue M et al. Impact of growth hormone (GH) treatment on cardivascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J. Clin. Endocrinol. Metab. 89, 2192-2199 (2004).
46. Peiris AN, Sothmann MS, Hoffmann RG et al. Adiposity, fat distribution, and cardiovascular risk. Ann. Intern. Med. 110(11), 867-872 (1989).
47. Bengtsson BA, Abs R, Bennmarker H et al. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J. Clin. Endocrinol. Metab. 84(11), 3929-3935 (1999).
48. Carroll PV, Christ ER, Bengtsson BA et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J. Clin. Endocrinol. Metab. 83(2), 382-395 (1998).
49. Sartorio A, Ferrero S, Conti A et al. Adults with childhood-onset growth hormone deficiency: effects of growth hormone treatment on cardiac structure. J. Intern. Med. 241(6), 515-520 (1997).
50. Cittadini A. Cuocolo A, Merola B et al. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am. J. Physiol 267(2 Pt 1), E219-E225 (1994).
51. Sacca L, Cittadini A, Fazio S. Growth hormone and the heart. Endocr. Rev. 15(5), 555-573 (1994).
52. Valcavi R, Gaddi O, Zini M et al. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J. Clin. Endocrinol. Metab. 80(2), 659-666 (1995).
53. Colao A, Di Somma C, Pivonello R et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J. Clin. Endocrinol. Metab. 87(3), 1088-1093 (2002).
54. Capaldo B, Patti L, Oliviero U et al. Increased arterial intima-media thickness in childhood-onset growth hormone deficiency. J. Clin. Endocrinol. Metab. 82(5), 1378-1381 (1997).
55. Markussis V, Beshyah SA, Fisher C et al. Abnormal carotid arterial wall dynamics in symptom-free hypopituitary adults. Eur. J. Endocrinol. 136(2), 157-164 (1997).
56. Sartorio A, Cattaneo M, Bucciarelli P et al. Alterations of haemostatic and fibrinolytic markers in adult patients with growth hormone deficiency and with acromegaly. Erp. Clin. Endocrinol. Diabetes 108(7), 486-492 (2000).
57. Sesmilo G, Biller BM, Llevadot J et al. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J. Clin. Endocrinol. Metab. 86(4), 1518-1524 (2001).
58. Pfeifer M, Verhovec R, Zizek B et al. Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. J. Clin. Endocrinol. Metab. 84(2), 453-457 (1999).
59. Smith JC, Evans LM, Wilkinson I et al. Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study. Clin. Endocrinol (Oxf.) 56(4), 493-501 (2002).
60. Leong KS, Mann P, Wallymahmed M et al. Abnormal heart rate variability in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 85(2), 628-633 (2000).
61. Leong KS, Mann P, Wallymahmed M et al. The influence of growth hormone replacement on heart rate variability in adults with growth hormone deficiency, Clin. Endocrinol (Oxf.) 54(6), 819-826 (2001).
62. Tanriverdi F, Eryol NK, Atmaca H et al. The effects of 12 months of growth hormone replacement therapy on cardiac autonomic tone in adults with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 62(6), 706-712 (2005).
63. Rosen T, Johannsson G, Johansson JO. Longterm effects of growth hormone replacement on cardiovascular risk factors. Endocrinol. Metab. 3(Suppl. A), 13-17 (1996).
64. Rosen T, Hansson T, Granhed H et al. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol. (Copenh.) 129(3), 201-216 (1993).
65. Davidson P, Milne R, Chase D et al. Growth hormone replacement in adults and bone mineral density: systematic review andmeta-analysis. Clin. Endocrinol. (Oxf.) 60(l), 92-98 (2004).
66. Wuster C, Abs R, Bengtsson BA et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J. Bone Miner. Res. 16(2), 398-405 (2001).
67. Abs R, Bengtsson BA, Hernberg-Stahl E et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin. Endocrinol. (Oxf.) 50(6), 703-713 (1999).
68. Abs R, Mattsson AF, Bengtsson BA et al. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Crowth Horm. IGF Res. 15(5), 349-359 (2005).
69. Drake WM, Coyte D, Camacho-Hubner C et al. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J. Clin. Endocrinol. Metab. 83(11), 3913-3919 (1998).
70. Golgeli A, Tanriverdi F, Suer C et al. Utility of P300 auditory event related potential latency in detecting cognitive dysfunction in growth hormone (GH) deficient patients with Sheehan's syndrome and effects of GH replacement therapy. Eur. J. Endocrinol. 150(2), 153-159 (2004).
71. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350), 563-566 (1998).
72. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396 (1998).
73. Orme SM, McNally RJ, Cartwright RA et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J. Clin. Endocrinol. Metab. 83(8), 2730-2734 (1998).
74. Hatrick AG, Boghalo P, Bingham JB et al. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur. J. Endocrinol. 146(6), 807-811 (2002).
75. Leung W, Rose SR, Zhou Y et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J. Clin. Oncol. 20(13), 2959-2964 (2002).
76. Swerdlow AJ, Reddingius RE, Higgins CD et at Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J. Clin. Endocrinol. Metab. 85(12), 4444-4449 (2000).
77. Hew FL, Koschmann M, Christopher M et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J. Clin. Endocrinol. Metab. 81(2), 555-564 (1996).
78. al Shoumer KA, Gray R, Anyaoku V et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol, (Oxf.) 48(6), 795-802 (1998).
79. Fowelin J, Attvall S, Lager I et al. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism 42(11), 1443-1447 (1993).
80. Hakkaart-van Roijen L, Beckers A. Stevenaert A et al. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 14(4), 395-403 (1998).
81. Verhelst J, Abs R, Vandeweghe M et al. Two years of replacement therapy in adults with growth hormone deficiency. Clin. Endocrinol. (Oxf) 47(4), 485-494 (1997).
82. Bengtsson BA, Johannsson G, Shalet SM et al. Treatment of growth hormone deficiency in adults. J Clin. Endocrinol. Metab. 85(3), 933-942 (2000).